Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Feb. 04, 2016 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, today announced that the company will be participating in two upcoming investor conferences.
- LEERINK Partners 5th Annual Global Healthcare Conferecne, February 11, 2016, New York
- RBC Capital Markets 2016 Global Healthcare Conference, February 23-24, 2016, New York
Arbutus’ President and CEO, Dr. Mark J. Murray, will present at the LEERINK conference on Thursday, February 11, 2016. A simultaneous webcast of the presentation can be accessed by visiting the Investor sections of www.arbutusbio.com and selecting Events and Presentations. Replays will be available on the Arbutus website following the event.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Our strategy is to target the three pillars necessary to develop a curative regimen for HBV: suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and, eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA that is the source of HBV persistence. Our portfolio of assets includes a broad pipeline of drug candidates for use in combination to develop a cure for HBV. To support continuous discovery of potential novel drug candidates and technologies, Arbutus has a research collaboration agreement with the Baruch S. Blumberg Institute that provides exclusive rights to in-license any intellectual property generated through the collaboration. The Baruch S. Blumberg Institute was established in 2003 by the Hepatitis B Foundation.
Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200
Email: [email protected]
Helia Baradarani
Manager, Investor Relations
Phone: 604.419.3200
Email: [email protected]
Media
Please direct all media inquiries to: [email protected]
